AbbVie reported a strong finish to 2025, with full-year adjusted EPS of $10.00 (beating guidance by $0.54) and total net revenues of $61.2 billion (up 8.6% operationally), driven by robust growth in Immunology and Neuroscience. The company exceeded initial revenue guidance by over $2 billion despite nearly $16 billion in HUMIRA erosion. For 2026, AbbVie projects continued momentum with total revenue growth of 9.5% to approximately $67 billion and adjusted EPS between $14.37 and $14.47, reflecting significant margin expansion. Key growth drivers include SKYRIZI and RINVOQ (expected combined sales >$31B in 2026), the ramp-up of 'Violet' for Parkinson's (forecasted blockbuster status), and double-digit growth in migraine products. Management also highlighted a recent voluntary agreement with the U.S. government involving a $100 billion R&D commitment.
| Metric | Value | Change |
|---|---|---|
| Q4 2025 Total Revenue | $16.6 billion | +10.0% (Op) |
| FY 2025 Total Revenue | $61.2 billion | +8.6% (Op) |
| FY 2025 Adjusted EPS | $10.00 | +$0.54 vs guidance midpoint |
| Q4 2025 Adjusted EPS | $2.71 | +$0.08 vs guidance midpoint |
| 2026 Revenue Guidance | $67 billion | +9.5% |
| 2026 EPS Guidance | $14.37 - $14.57 | N/A |
| SKYRIZI FY 2025 Sales | ~$5.0B (Q4) / ~$25.9B (Combined w/ RINVOQ) | +31.9% (Q4 Op) |
| HUMIRA FY 2025 Sales | $1.2 billion | -26.1% (Op) |
| Neuroscience FY 2025 Revenue | $10.7 billion | +~20% (implied absolute growth) |
Immunology Dominance and Market Share Expansion: AbbVie's core Immunology franchise is performing significantly above expectations, with SKYRIZI and RINVOQ generating combined sales of approximately $25.9 billion in 2025. Management raised the 2026 outlook for these assets to over $31 billion, effectively surpassing their previous 2027 long-term guidance by $500 million two years early. This is driven by market share gains, with SKYRIZI holding over 45% share in US psoriasis and maintaining a 75% in-play capture rate in frontline IBD, indicating strong competitive moats against entrants like Tremfya.
Neuroscience as a Primary Growth Engine: The Neuroscience division is emerging as a major profit driver, delivering over $10.7 billion in full-year 2025 revenue (up nearly $1.8 billion). The standout performer is the Parkinson's disease treatment 'Violet' (referred to as BIOLIF in guidance), which achieved $183 million in Q4 and is expected to reach blockbuster status ($1 billion+) in 2026. Additionally, the migraine franchise (UBRELVY and QULYPTA) is growing double-digit and is now projected to exceed $5 billion in peak sales, up from previous guidance of >$3 billion.
Oncology Pipeline Maturation and Combinations: AbbVie is strategically positioning its oncology portfolio through novel combinations, specifically integrating the newly acquired PD-1 VEGF bispecific antibody (from Remagen) with its cMet ADC, tmAbA. Management highlighted tmAbA as a 'multibillion-dollar opportunity' in colorectal cancer alone, with ongoing Phase 3 studies. This strategy aims to improve durability of response and survival, addressing a critical need in solid tumors and signaling a shift toward broader oncology utilization beyond hematologic malignancies.
Strategic Capital Allocation and Business Development: The company aggressively deployed capital in 2025, investing over $5 billion in business development to secure next-generation platforms. Deals focused on early-stage assets with high potential, such as an in vivo CAR-T platform (Capstan Therapeutics), a next-gen psychedelic (bradicilacin), and a long-acting amylin analog for obesity. This 'build and buy' strategy ensures a pipeline of growth drivers for the next decade, supported by a robust free cash flow forecast of $18.5 billion for 2026.
Proactive Government Engagement on Pricing: AbbVie secured a voluntary agreement with the U.S. government (referenced as the Trump administration) to mitigate pricing risks. The agreement includes a commitment of $100 billion in U.S. R&D and capital investments over the next decade. In exchange, AbbVie received exemptions from tariffs and future pricing mandates, including demonstration projects, providing a clearer regulatory runway for its price-protected assets like Botox and immunology drugs.
Aesthetics Franchise Contraction: The Aesthetics division faced continued headwinds in Q4, with global sales down 1.2% operationally. Management acknowledged that 'economic headwinds have continued to impact market conditions globally' and that category growth will remain 'challenged in 2026.' While Juvederm sales dropped 10.8%, even the flagship Botox Cosmetic saw only modest 3.8% growth, suggesting a broader demand softening in discretionary cosmetic procedures that could persist if macro conditions deteriorate.
IMBRUVICA Pricing and Competitive Pressure: IMBRUVICA sales declined by 20.8% operationally, and management warned that 'IMBRUVICA IRA pricing will unfavorably impact our oncology portfolio growth in 2026.' The drug faces significant competitive dynamics from BTK inhibitors and the Inflation Reduction Act (IRA) pricing mechanisms. The reliance on VENCLEXTA and pipeline assets to offset this decline creates execution risk, particularly as the oncology division was the only one to report negative operational growth in Q4 (-2.5%).
HUMIRA Erosion and Margin Drag: While anticipated, HUMIRA sales dropped 26.1% operationally, with further access decreases expected in 2026. Additionally, acquired IPR&D expenses created a significant drag on Q4 margins ($0.71 unfavorable impact on EPS and 7.6% impact on operating margins). Although guidance excludes future IPR&D, the heavy reliance on bolt-on acquisitions to fill the pipeline introduces integration risks and ongoing expense volatility that could dampen margin expansion if not managed strictly.
Pricing Headwinds for Key Growth Assets: Management admitted to facing 'low single-digit pricing headwinds' for both SKYRIZI and RINVOQ in 2026. Specifically, RINVOQ faces a 'high single-digit' unfavorable pricing comparison in Q1 due to prior year rebate timing. As these drugs become the company's profit drivers, their sensitivity to price rebates and market access negotiations could limit revenue upside relative to volume growth.
Overall: Management exhibited a highly confident and assured demeanor throughout the call, frequently using superlatives like 'excellent,' 'outstanding,' and 'exceptional' to describe performance. There was a notable lack of defensiveness regarding HUMIRA loss, as executives focused intently on the rapid uptake of new assets like SKYRIZI, RINVOQ, and Violet. The tone shifted to technical enthusiasm during the pipeline discussion, particularly regarding the psychedelic asset and oncology combinations.
Confidence: HIGH - Management provided specific, quantified guidance that exceeded previous long-term targets (e.g., SKYRIZI/RINVOQ surpassing 2027 guidance in 2026) and directly addressed competitive threats with concrete market share data (e.g., 75% capture rates in IBD). The specificity of the 2026 financial outlook, including a 48.5% operating margin, reinforces high conviction.
Approximately $67 billion (+9.5% growth)
$14.37 to $14.57
Approximately 48.5% (expansion from 2025)
$34.5 billion (SKYRIZI $21.5B, RINVOQ $10.1B)
$12.5 billion
$6.5 billion
$5.0 billion
Approximately $14.7 billion
$2.97 to $3.01
Hedging & Uncertainty: Management generally used direct, confident language regarding past performance and 2026 guidance, utilizing phrases like 'we expect' and 'we anticipate' frequently. However, hedging appeared when discussing longer-term pipeline assets and competitive dynamics. For example, Roopal Thakkar used qualifiers regarding the psychedelic asset: 'has the potential to be highly differentiated' and 'based on the favorable profile... emeraclidine will be moving forward.' Robert Michael also used temporal hedges regarding obesity: 'we will build upon as we identify other differentiated assets,' suggesting the strategy is not yet fully formed. The use of 'potential' was high in the R&D section ('potential multibillion-dollar emerging PD franchise'), which is standard for pipeline discussions but indicates uncertainty compared to the commercial business.
We delivered record net sales and exceeded our financial commitments. - Robert Michael, Chairman and CEO
SKYRIZI and RINVOQ... already surpassing our 2027 long-term guidance by half a billion. - Robert Michael, Chairman and CEO
We anticipate total sales growth of 9.5%, reflecting another year of robust sales results. - Robert Michael, Chairman and CEO
We're very, very comfortable with the momentum that we're gonna continue to see with SKYRIZI. - Jeffrey Stewart, Chief Commercial Officer
We have plenty of firepower to pursue both early and late-stage opportunities. - Robert Michael, Chairman and CEO
We do not see a large or meaningful interaction between the two [Botox pricing] even if we do see the negotiation take place. - Jeffrey Stewart, Chief Commercial Officer
This short-acting psychedelic demonstrated very strong durable efficacy... has the potential to become a groundbreaking new treatment. - Roopal Thakkar, Chief Scientific Officer
Analyst Sentiment: Analysts were generally inquisitive about the sustainability of growth in competitive markets (IBD, Migraine) and the specifics of the pipeline (Psychedelic, Obesity). There was skepticism regarding the 'inevitable impact' of IBD competition and the 'protracted downturn' in Aesthetics. Questions were direct and focused on quantifying risks (e.g., pricing headwinds, Botox Medicare negotiation).
Management Responses: Management responses were assertive and data-driven, often correcting analyst premises. They refuted competitor claims in Migraine by citing revenue differentials and defended IBD share with specific capture rates (75%). They displayed deep knowledge of pipeline assets (e.g., specific dosing strategies for the psychedelic) and maintained a positive outlook on Aesthetics despite macro headwinds, framing new product launches as catalysts.
Immunology Competition (IBD/Psoriasis): Analysts pressed on the impact of Tremfya and other IL-23 inhibitors. Management emphasized high 'in-play' capture rates (75-80%) and the expansion of the overall IL-23 category, arguing it is not a zero-sum game.
Migraine Market Share: Analysts asked about Pfizer's share gains in primary care. Robert Michael countered by citing AbbVie's $1 billion revenue lead and superior growth trajectory, dismissing the competitor's data.
Aesthetics & Botox Pricing: Discussion centered on the impact of Medicare negotiation on Botox and the macroeconomic downturn. Management clarified that the cosmetic and therapeutic pricing are largely decoupled and that the Medicare selection was already modeled into guidance.
Pipeline Specifics (Psychedelic & Obesity): High interest in the mechanism of action for the psychedelic (bradicilacin) and the differentiation of the Amylin analog (ABBV 295) for obesity. Management highlighted the 'short-acting' nature of the psychedelic and the tolerability profile of the Amylin drug.
Business Development: Analysts inquired about the appetite for large vs. small deals. Robert Michael confirmed capacity for both early and late-stage deals, emphasizing 'firepower' and a focus on core therapeutic areas.
AbbVie has successfully navigated the HUMIRA patent cliff, delivering 8.6% operational growth in 2025 and setting up for another strong year in 2026 (9.5% growth) driven by the Immunology duo (SKYRIZI/RINVOQ) and a resurgent Neuroscience franchise. The company's guidance of $14.37-$14.57 EPS implies significant margin expansion and demonstrates strong operating leverage. The pipeline is maturing with high-value catalysts in Parkinson's (Violet), Oncology (TmAbA), and Immunology (RINVOQ/Vitiligo), while the aggressive BD strategy ($5B+ spend) mitigates long-term LOE risks. The recent US government agreement provides a layer of protection against regulatory pricing risks. While Aesthetics and IMBRUVICA present headwinds, they are more than offset by the momentum in the core growth drivers. The stock offers a compelling combination of yield, growth, and pipeline optionality.
AbbVie secured a voluntary agreement with the US government (Trump Administration) that exempts the company from tariffs and future pricing mandates (including demonstration projects) for three years. In exchange, AbbVie committed $100 billion to US R&D and capital investments. This deal reduces regulatory overhang for key assets like Botox and immunology drugs.
Management noted that 'economic headwinds have continued to impact market conditions globally' for Aesthetics. This suggests that consumer spending on elective procedures remains under pressure, particularly in markets like Brazil, impacting growth for Juvederm and Botox Cosmetic.
The company expects a favorable FX impact of roughly 0.8% on full-year 2026 sales growth, providing a modest tailwind to the top-line guidance.